On the upside
A Seeking Alpha contributor expects Sprint (NYSE: S) reverse losses to post a profit in the near future.
Peregrine Pharmaceuticals (Nasdaq: PPHM) narrowed first quarter losses as expenses fell.
On the downside
Geron (Nasdaq: GERN) stopped a mid-stage trial of its breast cancer treatment imetelstat because it was ineffective. Zalicus (Nasdaq: ZLCS) ended development of its rheumatoid arthritis treatment Synavive after failed a Phase 2b clinical trial.
Plain Exploration & Production (NYSE: PXP) will pay approximately $5.55 billion to acquire Gulf of Mexico assets from BP (NYSE: BP).
In the broad market, declining issues outpaced advancers by a slim margin on the NYSE and by more than 9 to 7 on Nasdaq. The Russell 2000 which tracks small cap stocks eased a point to 841.